Astrocyte Pharmaceuticals Inc.
PrivateLast Round
Series B
Sep 30, 2026
Total Funding Raised
$36.97M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Astrocyte Pharmaceuticals Inc. is a biotechnology company developing novel neuroprotective therapeutics for the treatment of stroke, traumatic brain injury, concussions, and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Astrocyte Pharmaceuticals Inc. Comparables
Compare Astrocyte Pharmaceuticals Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeuroTrauma Sciences | 87% | |
| Owl Therapeutics | 83% | |
| TIBEAY Biosciences | 83% |
Astrocyte Pharmaceuticals Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 30, 2026 | ||||
| Grant | Aug 25, 2026 | ||||
| Grant | Jun 17, 2025 | ||||
| Early Funding | Aug 18, 2023 | ||||
| Grant | Jun 7, 2023 | ||||
Grant | Sep 16, 2021 |
Astrocyte Pharmaceuticals Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SideCar Angels | Early Funding, Series A, Seed |
| National Institute on Drug Abuse | Grant |
| Dreavent Capital | Early Funding |
| Waterstar Capital | Series B |
| Nest.Bio | Seed, Early Funding |
| CR Ventures | Series A |
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 30, 2026
$9.5M round led by DeepWork Capital.
- Aug 25, 2026
$400K grant from National Institute on Drug Abuse and NIH.
Recent news
Latest coverage and updates
- is_developingSep 30, 2026
Astrocyte Pharmaceuticals Inc. is developing therapeutic drug on Sep 30th '26.
- receives_financingSep 30, 2026
Astrocyte Pharmaceuticals Inc. receives $9.5M Series B financing in Connecticut on Sep 30th '26
Astrocyte Pharmaceuticals Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Astrocyte Pharmaceuticals Inc.'s valuation, stock price, and market status.
Is Astrocyte Pharmaceuticals Inc. a public or private company?
Astrocyte Pharmaceuticals Inc. is a private company.
What is the current stock price of Astrocyte Pharmaceuticals Inc.?
Astrocyte Pharmaceuticals Inc. is a private company, so its shares have no public market price. Caplight tracks Astrocyte Pharmaceuticals Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Astrocyte Pharmaceuticals Inc. worth (valuation)?
Valuation information for Astrocyte Pharmaceuticals Inc. is not publicly available.
Can I buy Astrocyte Pharmaceuticals Inc. stock?
Astrocyte Pharmaceuticals Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Astrocyte Pharmaceuticals Inc.'s last funding round?
Astrocyte Pharmaceuticals Inc.'s most recent funding round was Series B on September 30, 2026.
Who are the main investors in Astrocyte Pharmaceuticals Inc.?
Key investors in Astrocyte Pharmaceuticals Inc. include Dreavent Capital, DeepWork Capital, Boston Harbor Angels.
Will Astrocyte Pharmaceuticals Inc. IPO soon?
No public IPO plans have been announced for Astrocyte Pharmaceuticals Inc..
How can I track Astrocyte Pharmaceuticals Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Astrocyte Pharmaceuticals Inc.'s shares on secondary markets.